Argent BioPharma has recast itself as an immune science company. In an update to shareholders, it said it will now focus its resources and research on inflammatory disease after licensing CannEpil to ...
Racura Oncology has been given the go-ahead to raise the dose in its HARNESS-1 lung cancer trial after a safety review found no dose-limiting toxicities in the first patients treated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results